• Attivo Networks

  Participated · Series B · May 2017

  Attivo Networks develops deception technology that uses decoys and lures to detect, misdirect, and analyze in‑network attacks. Its Attivo ThreatDefend Deception Platform includes network, endpoint, application, and data deceptions and can emulate ICS and SCADA systems for operational technology environments. The platform's attack analysis engine automates gathering of threat intelligence, correlating attack data, and responding to alerts, reducing investigation time from hours to minutes. The company says advanced machine‑learning simplifies preparation, deployment, and operations, and it has won over 75 awards for its technology and leadership. As part of a strategic push into utilities, Attivo is expanding its energy sector‑specific deception portfolio and increasing go‑to‑market activities to broaden its utility customer base. Energy Impact Partners has invested in the company as a strategic investor; financial terms were not disclosed. Attivo is based in Fremont, CA. Attivo Networks is a Fremont, CA–based provider of deception solutions for cybersecurity defense. Led by CEO Tushar Kothari, the company develops the Attivo ThreatDefend™ Deception and Response Platform for real-time detection, analysis, and accelerated response to advanced, credential, insider, Active Directory and ransomware attacks. The platform detects advanced in-network threats and provides scalable continuous threat management across user networks, data centers, cloud, IoT, ICS‑SCADA, and POS environments. Advanced attack analysis and lateral movement tracking are auto-correlated for evidence-based alerts, forensic reporting, and automatic blocking and quarantine of attacks. The company raised $21m in Series C funding and intends to use the funds to further develop the ThreatDefend platform and expand global sales initiatives. The round brings total funding to $45.7m. Attivo Networks offers the Attivo Deception and Response Platform for real-time detection, analysis and accelerated response to advanced, credential, insider, and ransomware attacks. The platform detects in-network threats and provides scalable continuous threat management across user networks, data centers, cloud, IoT, ICS-SCADA, and POS environments. The company serves organizations across financial, healthcare, technology, retail, and energy sectors and has seen strong adoption of deception technology for early detection and accelerated response. Led by CEO Tushar Kothari, Attivo focuses on detecting threats that have bypassed prevention security. The company plans to use new funding to further develop platform functionality and expand global sales initiatives. No revenue or user metrics were disclosed in the article. Attivo Networks provides an advanced threat detection solution that uncovers BOTs and APTs as they move laterally within an organization’s network and data center using honeynet technology and patented techniques. The solution is targeted at enterprise environments and is deployed to detect sophisticated lateral movement. The company serves customers in the healthcare, banking, and technology sectors. Leadership includes CEO Tushar Kothari, Executive VP Mano Murthy, and SVP of Engineering Srikant Vissamsetti. Attivo plans to use newly raised funds to increase investment in product development and customer support. Financially, the company secured $8M in Series A financing in April 2015.

• Catalia Health

  Participated · Seed · May 2017

  Catalia Health is a San Francisco–based patient care management company founded in 2014 that offers an AI-powered personal healthcare companion called Mabu. The platform combines artificial intelligence, psychology and medical best practices to support patients managing chronic illnesses and to deliver daily, tailored check-ins. Mabu is deployed to help patients with conditions such as rheumatoid arthritis, late-stage kidney disease and congestive heart failure and to provide clinicians insight on adherence and patient status. Catalia positions its technology against a U.S. population of roughly 117 million people managing chronic conditions and targets improved medication adherence, symptom management and reduced readmissions. The company announced a hire for Director of Product Management to oversee the platform roadmap as it prepares clinical and commercial rollout. Catalia Health provides an AI-powered patient engagement platform that pairs proprietary conversation-generation algorithms with a social robot, Mabu, to engage patients, collect data, and support care management. The platform targets chronic-disease management and medication adherence, aiming to improve symptom management and reduce hospital readmissions. Catalia plans to build and deploy its care management system across its first three disease states and begin patient rollout in its first two disease states in early summer 2017. The company emphasizes scalable, personalized conversations to increase adherence and monitor patient health. Catalia was founded in 2014 and is based in San Francisco; Dr. Cory Kidd is CEO and founder. Financially, the company has completed a seed extension following an earlier seed round to fund product deployment and data collection. Catalia Health develops Mabu, a social robot designed to provide information and support for patients with chronic diseases such as diabetes, arthritis, cancer and heart disease. The company is pitching Mabu to healthcare providers and pharmaceutical companies to augment doctors and help manage large patient populations. Catalia has an alpha prototype in its offices and plans to scale production and deployment. The firm expects to have the first robots on the market by the end of the year and is already in discussions with several early potential customers. Founded by Cory Kidd using work that began at MIT’s Media Lab and evolved through his prior company Intuitive Automata, Catalia is positioning Mabu around engagement and the psychology of interaction. The company will use the recent financing to scale up its business.

No current team members are available.